Journal
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
Volume 41, Issue 2, Pages 127-133Publisher
WILEY
DOI: 10.1111/1440-1681.12194
Keywords
adenosine monophosphate-activated protein kinase; diabetic cardiomyopathy; Na+/K+-ATPase; sirtuin 1
Categories
Funding
- National Nature Science Foundation of China [81102437]
Ask authors/readers for more resources
1. Decreased Na+/K+-ATPase activity, and both sirtuin 1 (SIRT1) and adenosine monophosphate-activated protein kinase (AMPK) have been reported to be involved in the development of diabetic cardiomyopathy (DCM). 2. The present study aimed to investigate the advanced glycation end-products (AGE) that impair Na+/K+-ATPase stability by regulating the AMPK/SIRT1 pathway during progression of DCM. 3. To study type 1 diabetic mellitus (T1DM), a disease model in rats was established by a single intraperitoneal injection of streptozotocin (STZ; 65 mg/kg), and neonatal rat cardiomyocytes were also cultured. Heart function was detected by Doppler, and SIRT1 and AMPK protein expression were detected by immunohistochemistry and western blotting. Na+/K+-ATPase activity was also monitored. 4. Using in vivo rat models of DCM, we showed that Na+/K+-ATPase activity decreased when both AMPK and SIRT1 expression were downregulated. In vitro, AGE impaired Na+/K+-ATPase activity and decreased the AMPK and SIRT1 expression. 5. Sirtuin 1 overexpression increased Na+/K+-ATPase activity. 5-aminoimidazole-4-carboxamide-3-ribonucleoside (AICAR) upregulated SIRT1 expression and increased Na+/K+-ATPase activity, which could be partially abolished by splitomicin. 6. Our results suggest that the dysfunction of DCM is related to AGE-induced Na+/K+-ATPase activity impairment through a mechanism involving the AMPK/SIRT1 pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available